中国临床药学杂志

参考文献

[1]MAGILL S S,O'LEARY E,JANELLE S J,et al.Changes in prevalence of health care-associated infections in U.S.hospitals[J].N Engl J Med,2018,379(18):1732.

[2]吴安华,文细毛,李春辉,等.2012年全国医院感染现患率与横断面抗菌药物使用率调查报告[J].中国感染控制杂志,2014,13(1):8.

[3]施毅.中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J].中华结核和呼吸杂志,2018,41(4):255.

[4]AILAWADI G, CHANG H L,O'GARA P T,et al.Pneumonia after cardiac surgery:experience of the national institutes of health/Canadian institutes of health research cardiothoracic surgical trials network[J].J Thorac Cardiovasc Surg,2017,153(6):1384.

[5]KALIL AC,METERSKY ML,KLOMPAS M,et al.Management of adults with hospital-acquired and ventilator-associated pneumonia:20 16 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J].Clin Infect Dis,2016,63(5):e61.

[6]SPELLBERG B,TALBOT G H,BRASS E P, et al.Positionpaper:recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia[J].Clin Infect Dis,2008,47(Suppl 3):S249.

[7]郑少微,李萍,张正良,等.2005-2017年中国CHINET常见革兰阴性菌对碳青霉烯类抗生素耐药的监测结果[J].临床急诊杂志,2019,20(1):45.

[8]PANG Z, RAUDONIS R,GLICK B R,et al.Antibiotic resistance in Pseudomonas aeruginosa:mechanisms and alternative therapeutic strategies[J].Biotechnol Adv,2019,37(1):177.

[9]MARQUES A S,CASTRO J N F,COSTA F J M D,et al.Nearinfrared spectroscopy and variable selection techniques to discriminate Pseudomonas aeruginosa strains in clinical samples[J].Microchem J,2016,124:306.

[10]LOUIE A, GRASSO C,BAHNIUK N, et al.The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression[J].Antimicrob Agents Chemother,2010,54(6):2646.

[11]LOUIE A,LIU W,ANGUILDER M,et al.Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia[J].J Infect Dis, 2015,211(8):1326.

[12]CHAMOT E,BOFFI EL AMARI E,ROHNER P, et al.Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia[J].Antimicrob Agents Chemother,2003,47(9):2756.

[13]TSCHUDIN-SUTTER S, FOSSE N, FREI R,et al.Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections[J].PLoS One,2018,13(9):e0203295.

[14]TAMMA P D,AITKEN S L,BONOMO R A,et al.Infectious diseases society of America guidance on the treatment of extendedspectrum β-lactamase producing enterobacterales(ESBL-E),carbapenem-resistant enterobacterales(CRE),and Pseudomonas aeruginosa with difficult-to-treat resistance(DTR-P.aeruginosa)[J].Clin Infect Dis,2021,72(7):e169.

[15]陈涛,徐晔,董郭枫,等.头孢他啶/阿维巴坦单独和联合磷霉素碳青霉烯类耐药革兰阴性菌体外抗菌活性研究[J].检验医学,2020,35(10):988.

[16]KWA A,KASIAKOU S K,TAM V H,et al.Polymyxin B:similarities to and differences from colistin(polymyxin E)[J].Expert Rev Anti Infect Ther,2007,5(5):811.

[17]FALAGAS M E,KASIAKOU S K.Toxicity of polymyxins:a systematic review of the evidence from old and recent studies[J].Crit Care,2006,10(1):R27.

[18]TSUJI B T, POGUE J M,ZAVASCKI A P, et al.International consensus guidelines for the optimal use of the polymyxins:endorsed by the American college of clinical pharmacy(ACCP),European society of clinical microbiology and infectious diseases(ESCMID),infectious diseases society of America(IDSA),international society for anti-infective pharmacology(ISAP),society of critical care medicine(SCCM),and society of infectious diseases pharmacists(SIDP)[J].Pharmacotherapy,2019,39(1):10.